| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | -8.7% | -43.4% |
| R&D Expense | $25.8M | -5.8% | -25.4% |
| SG&A Expense | $10.6M | -7.1% | -48.9% |
| Operating Income | -$34.7M | +6.0% | +33.7% |
| Net Income | -$32.3M | +5.3% | +32.4% |
| EPS (Basic) | -$0.27 | +6.9% | +32.5% |
| EPS (Diluted) | -$0.27 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $40.6M | -1.5% | +7.2% |
| Short-term Investments | $174.8M | -3.7% | -32.5% |
| Accounts Receivable | $682K | -51.1% | -83.5% |
| Current Assets | $221.3M | -4.0% | -28.7% |
| Total Assets | $343.7M | -7.5% | -30.6% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$82.8M | — | — |
| Capital Expenditures | $4.8M | — | — |
| Investing Cash Flow | $83.5M | — | — |
| Financing Cash Flow | $3.8M | — | — |
| Free Cash Flow | -$87.5M | — | — |
| +6.9% |
| +32.5% |
| $28.1M |
| -2.0% |
| -24.9% |
| Stockholders' Equity | $234.1M | -10.4% | -35.4% |